Reviva Pharmaceuticals -CW23RVPHWPreferred / convertible
13F holders, Q4 2024 (December 31)2holders −1
1new positions
2sold out
$0.16avg. 13F price*
At the end of Q4 2024, 2 institutions reported holding Reviva Pharmaceuticals -CW23 (RVPHW) in their 13F filings, down 1 from Q3 2024. 1 opened new positions and 2 sold out. The largest holders were UBS Group AG ($612) and Clear Street LLC ($16).
- Company
- Reviva Pharmaceuticals -CW23
- CUSIP
- 76152G118
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $16 |
| Exits | 2 | $8K |
All 13F filers, Q3 2024 → Q4 2024: 3,168 shares bought and 59,445 shares sold, net −56,277 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| UBS Group AG | — | Add +460.7% | 3,734 | $612 |
| Clear Street LLC | — | New | 100 | $16 |
"% of holder's portfolio" is RVPHW's weight in each manager's 13F, not the share of Reviva Pharmaceuticals -CW23 the manager owns.